| |
The U.S. colonic stents market was valued at $6.44 million in 2018 and is projected to reach $9.41 million by 2026, registering a CAGR of 4.8% from 2019 to 2026. A colonic stent is used to relieve acute colonic obstruction in colorectal cancer patients. The stent is compressed tightly onto a small delivery wire that allows the stent to be positioned across the tight narrowing to relieve blockage in the colon. Once opened, it relieves the obstruction by keeping the colon open that can take up to 24 hours for the stent to fully open. However, stents can be used when there is either a partial or complete blockage in the bowel to reduce the pressure in the bowel and relieve the obstruction. Further, stents are also used when surgery is not recommended as an alternative to keep the bowel working. It is usually performed by specialist doctors including endoscopist or by an interventional radiologist in the X-ray department.
Significant rise in incidences of colorectal cancer and benign strictures in the U.S are the major factors driving the U.S. colonic stents market. In addition, increase in demand for minimally invasive procedures and technological advancements regarding the development of more compatible metallic stents further propels the market growth of colonic stents in the near future. However, complications and high costs associated with colonic stents is anticipated to hamper the growth of the colonic stents market in the U.S. Moreover, colonic stenting improves the primary anastomosis rate with a low stoma creation in comparison with emergency surgery. Improved colonic stent such as self-expandable metallic stents (SEMS) is used for the bridge to surgery and it also able to cure patients with the palliative intent with advanced neoplastic disease, to avoid stoma and health care costs related to stoma. This provides a lucrative opportunity for the growth of the U.S. colonic stents market.
The report covers the U.S. colonic stents market forecast and analysis based on three categories that include product type, indication, and end user. Based on product type, the market is categorized into nitinol self-expandable metal stents, and elgiloy self-expandable metal stents. On the basis of indication, it is categorized into colorectal cancer, colonic benign strictures and others. By end user, the market is bifurcated into hospitals and specialty clinics.
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current U.S. colonic stents market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
Key Market Segments
By Product Type
Self-Expandable Metal Stents
o Nitinol Stent
o Elgiloy
By Indication
• Colorectal Cancer/Bridge to Surgery
• Benign Colonic Strictures
• Other Indications
By End User
• Hospitals
• Specialty Clinics
The key players profiled in this report are as follows:
• Boston Scientific Corporation
• Cook Medical Inc
• Cook Medical Inc
• Taewoong
• MI-TECH
• Olympus Corporation
|
The global urinary self-catheters market was valued at $1,722 million in 2018, and is projected to reach $2,387 million by 2026, registering a CAGR of 4.1% from 2019 to 2026.
A urinary catheter is a hollow, partially flexible tube, which is used to drain the urine when an individual is unable to do it naturally. These catheters consist of a drainage bag that assists to collect a urine. They are composed of silicone, PVC, or vinyl or red rubber latex.
The urinary self-catheter market is expected to exhibit significant market growth during the forecast period, owing to increase in prevalence of benign prostate hyperplasia (BPH), urinary incontinence, and spinal cord injuries; rise in number of surgeries, and increase in geriatric population. Upsurge in demand for hydrophilic intermittent catheters and favorable reimbursement policies for usage of urinary catheters further supplement the market growth.
Innovations in catheters, novel product launches, and rise in demand for intermittent catheters in emerging economies provide lucrative opportunities for the market expansion. However, the availability of substitutes of catheters and lack of awareness toward utilization of self-catheters hamper the market growth.
The global urinary self-catheters market is segmented based on product, type, application, and region. Depending on product, the market is bifurcated into intermittent catheters and external catheters. Intermittent catheters are further classified into uncoated intermittent catheters and coated intermittent catheters. Coated intermittent catheters are subsegmented into antimicrobial, hydrophilic, and others. According to type, the market is categorized into male type catheter and female type catheter. By application, it is divided into benign prostate hyperplasia (BPH), urinary incontinence, spinal cord injuries, and others. Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Taiwan, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, Turkey, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Product
• Intermittent Catheter
o Uncoated Intermittent Catheters
o Coated Intermittent Catheters
? Antimicrobial Intermittent catheters
? Hydrophilic Intermittent catheters
? Others
• External Catheter
Type
• Male Type Catheter
• Female Type Catheter
Application
• Benign Prostate Hyperplasia (BPH)
• Urinary Incontinence
• Spinal Cord Injuries
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Taiwan
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Turkey
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Asid Bonz GmbH
• B Braun Melsungen AG
• Becton Dickson and Company (C.R. Bard)
• Boston Scientific Corporation
• Coloplast A/S
• ConvaTec
• Hollister, Inc.
• Medical Technologies of Georgia, Inc.
• Medtronic plc.
• Teleflex Incorporated
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• Cure Medical
• Pennine Healthcare
|
Natural killer (NK) cell is a component of innate immunity system that targets cancer cells, and can be used as a therapeutic agent. NK cells target the cells losing MHC-I in cancer, a phenotype that is similar to certain cells in immune-privileged sites whose milieus are separated from peripheral blood.
The global natural killer cell therapeutics market was valued at $1,402 million in 2018, and is projected to reach $5,096 million by 2026, registering a CAGR of 17.4% from 2019 to 2026.
The growth of the global natural killer cell therapeutics market is driven by rise in use of NK cells to treat cancer, infections, and liver diseases. Moreover, NK cells play vital role in tumor immune-surveillance, which has significantly boosted their adoption across the globe. In addition, rise in awareness among the population regarding various immunotherapies and increase in R&D for the development of bi-specific antibody for engaging NK cells to eliminate tumor cells propel the global natural killer cell therapeutics market growth. However, lack of specificity and poor in-vivo survival of the cells limit the growth of the market. Furthermore, higher costs associated with the therapies and adverse side effects are expected to hamper the market growth in the coming years. Conversely, significant surge in R&D activities toward development of immunotherapy in developing economies is anticipated to offer lucrative opportunities for the market.
The global natural killer cell therapeutics market is segmented based on therapeutics, application, end user, and region. Depending on therapeutics, the natural killer cells therapeutics market is classified into NK cell therapies and NK cell directed antibodies. By application, it is categorized into cancer, gastrointestinal diseases, immunoproliferative disorders, and others. On the basis of end user, it is segregated into hospitals, research centers & institutes, and others. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The global natural killer cell therapeutics market size and estimations are based on a comprehensive analysis of key developments.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
• By Therapeutics
o NK Cell Therapies
o NK Cell Directed Antibodies
• By Application
o Cancer
o Gastrointestinal Diseases
o Immunoproliferative Disorders
o Others
• By End User
o Research Centers & Institutes
o Hospitals
o Others
• By Region
o North America
? U.S.
? Canada
? Mexico
o Europe
? Germany
? France
? UK
? Italy
? Spain
? Rest of Europe
o Asia-Pacific
? Japan
? China
? India
? Australia
? Rest of Asia-Pacific
o LAMEA
? Brazil
? Saudi Arabia
? South Africa
? Rest of LAMEA
The key players profiled in this report are as follows:
• Affimed N.V.
• Celgene Corporation
• Fate Therapeutics
• Fortress Biotech
• Glycostem Therapeutics BV
• Innate Pharma S.A.
• Nantkwest Inc.
• Nkarta Therapeutics, Inc.
• NKT Therapeutics Inc.
• Ziopharm Oncology Inc.
|
The global multiplex assays market accounted for $73.2 million in 2018, and is expected to reach $123.1 million by 2026, growing at a CAGR of 6.6% from 2019 to 2026.
Multiplex immunoassays conjugates assays for several target analytes in a single reaction volume, minimizing workflow and sample volume difficulties. In addition, this assay provides a gain in assay dynamic range, and is used to amplify multiple targets in a polymerase chain reaction (PCR) and collect more information from minute quantities of proteins or other analytes in lesser time as compared to conventional methods such as singleplex ELISA. Multiplex assays finds its application in pathogen identification, mutation analysis, RNA detection, gene detection analysis, linkage analysis, forensic studies, and others.
Multiplex assays hold enormous potential in the R&D of drugs for the treatment of diseases, such as cancer and cardiovascular diseases that drives the market growth for theses assays. For instance, bead-based Luminex xMAP multiplex assay provides a platform for cancer biomarker assays, which are compatible with plasma, serum, cultured cells, and other biological samples. In addition, surge in adoption of multiplex assays to reduce operation costs and rise in adoption of personalized medicines are anticipated to boost the market growth. However, high capital investment and dearth of skilled labors are the major factors that hinder the market growth. On the contrary, the emerging economies of Asia-Pacific and LAMEA regions offer lucrative growth opportunities for the expansion of multiplex assays market, due to improvement in healthcare infrastructure in these regions and increase in demand for better healthcare services from majority of the patient population.
The global multiplex assays market in this report is studied based on type, product, technology, application, end user, and region. On the basis of type, the market is divided into nucleic acid-based, protein-based multiplex assays, and others. By product, it is classified into multiplex assay reagents & consumables, multiplex assay instruments & accessories, and multiplex assay software & services. Depending on technology, it is fragmented into nucleic acid-based, protein-based multiplex assays, and others. As per application, it is segregated into companion diagnostics, research & development, clinical diagnostics, and others. According to end user, it is classified into hospitals, clinical laboratories, research institutes, and pharmaceuticals & biotechnological companies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
? The study provides an in-depth analysis of the global multiplex assay market along with the current trends and future estimations to elucidate the imminent investment pockets.
? A comprehensive analysis of the factors that drive and restrict the market growth is provided.
? A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
? An extensive analysis of the key segments of the industry helps to understand the global trends in the multiplex assay market.
? Key players and their strategies are provided to understand the competitive outlook of the industry.
? KEY MARKET SEGMENTS
By Type
• Nucleic Acid-based Multiplex Assays
• Protein-based Multiplex Assays
• Others
By Product
• Multiplex Assay Reagents & Consumables
• Multiplex Assay Instruments & Accessories
• Multiplex Assay Software & Services
By Technology
• Multiplex PCR
• Multiplex Protein Microarray
• Others
By Application
• Companion Diagnostics
• Research & Development
• Clinical Diagnostics
End User
• Hospitals
• Clinical Laboratories
• Research Institutes
• Pharmaceuticals & Biotechnological Companies
By Region
o North America
• U.S.
• Canada
• Mexico
o Europe
• UK
• France
• Germany
• Italy
• Spain
• Rest of Europe
o Asia-Pacific
• Japan
• China
• India
• South Korea
• Australia
• Rest of Asia-Pacific
o LAMEA
• Saudi Arabia
• South Africa
• Brazil
• Rest of LAMEA
KEY MARKET PLAYERS
• Luminex Corporation
• Thermo Fisher Scientific Inc.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN N.V.
• Becton, Dickinson and Company
• Abcam PLC
• Seegene Inc.
• Randox Laboratories Ltd.
The other players in the value chain include (profiles not included in the report)
• Merck KGaA
• Agilent Technologies
• Quanterix
• Olink
• Sysmex Corporation
• Siemens Healthcare GmbH
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
|
The Vietnam menstrual cups market size was $1.521 million in 2018 and is projected to reach $2.264 million by 2026, registering a CAGR of 5.2% from 2019 to 2026.
A menstrual cup is a feminine hygiene product that is used during menstruation. It is inserted into the vagina and one can keep it inside for a maximum duration of 12 hours. Its purpose is to prevent menstrual blood from leaking onto the clothes. It is made up of either latex, silicone, or thermoplastic elastomer. Silicon and thermoplastic elastomer are hypoallergic, which means that the wearer can be safe from unwanted irritation and allergies. The menstrual cups are available in smaller and larger size, where smaller size is recommended for women under 30 (who have not given birth vaginally) and the larger size is recommended for women who are over 30 (have given birth vaginally or experience a heavy flow).
The major factors that drive the growth of the Vietnam menstrual cups market include increase in awareness among the population about the available options during menstruation. Huge number of awareness campaigns conducted by women communities, educational institutes, and non-profit organizations also help in the growth of the market. In addition, rise in women populace coupled with high costs of sanitary pads and tampons further fuels the market growth. However, additional substitutes coupled with high cost of menstrual cups as well as cultural resistance & limited level of acceptance of these sanitary protections are expected to hamper the market growth. On the contrary, rise in awareness about eco-friendly and safety sanitary protections is anticipated to create lucrative opportunities for the menstrual cup manufacturers in Vietnam in the near future.
The Vietnam menstrual cups market is segmented based on product type, material, and distribution channel. Based on product type, the market is bifurcated into disposable menstrual cups and reusable menstrual cups. Based on material, the market is divided into medical grade silicones, natural latex rubber, and thermoplastic elastomer. Based on distribution channel, the market is categorized into online stores and pharmacies/retail stores.
KEY BENEFITS FOR STAKEHOLDERS
? This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
? A comprehensive analysis of the factors that drive and restrain the growth of the Vietnam menstrual cups market is provided.
? An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
• By Product Type
o Reusable Menstrual Cups
o Disposable Menstrual Cups
• By Material
o Medical grade silicones
o Natural Latex Rubber
o Thermoplastic elastomer
• By Distribution Channel
o Online Stores
o Pharmacies/Retail Stores
KEY MARKET PLAYERS
• Anigan
• Diva International Inc.
• Fleurcup
• Jaguara, s.r.o.
• Lingroup Co., Ltd. (Lintimate)
• Lune Group Oy Ltd.
• Lena Cup
• Mooncup Ltd.
• Me Luna GmbH
• OVA Vietnam Company Limited
• Sterne (Si-Line)
• YUUKI Company s.r.o.
|
The global menstrual cup market accounted for around $1,213 million in 2018 and is expected to reach $1,894 million by 2026, registering a CAGR of 5.7% from 2019 to 2026. A menstrual cup is a feminine hygiene product that are used during menstruation. It is inserted into the vagina and one can keep it inside for maximum 12 hours. Its purpose is to prevent menstrual blood from leaking onto the clothes. It is made up of either latex, silicone, or thermoplastic elastomer. Silicon and thermoplastic elastomer are hypoallergic which means that the wearer can be safe from unwanted irritation and allergies. The menstrual cups are available in a smaller and a larger size, where smaller size is recommended for women under 30 (who have not given birth vaginally) and the larger size is recommended for women who are over 30 (have given birth vaginally or have a heavy flow).
The menstrual cup market is expected to witness significant growth during the forecast period due to the factors such as rise in demand & increase in awareness for advanced feminine hygiene products. Moreover, menstrual cups also help prevent odor, hold more blood than pads or tampon, and are more hygienic as compared to the pads and tampons. These menstrual cups are made up of the medically graded researched material making them safe to be inserted into the body. However, the menstrual cups can be messier to use, and hard to insert & remove. Sometimes menstrual cups can also cause allergic reaction, which hinders the growth of the menstrual cup market. However, increase in focus on product innovation for feminine hygiene products and emphasizing on production of menstrual cup made from organic and biodegradable materials can help open new avenues for the growth of menstrual cup market.
The global menstrual cup market is segmented based on product type, material type, and end user. Based on product type, the market is bifurcated into disposable and reusable menstrual cup. Based on material type, the market is classified into medical grade silicone, natural gum rubber (latex) and thermoplastic elastomer (TPE). Based on distribution channel, the market is categorized into online stores and pharmacies & retail stores. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major key players operating in menstrual cup market are Diva International Inc., Lunette, The Keeper, Inc., Femcap, Mooncup Ltd., Fleurcup, MeLuna USA, Lena Cup, Lingroup Co., Ltd., Jaguara, s.r.o, Anigan, Vcup, and Yuuki Company s.r.o.
KEY BENEFITS FOR STAKEHOLDERS
? This report highlights the market dynamics to understand the global Menstrual Cup market and capitalize on the prevailing opportunities.
? Quantitative analysis of the current market and forecasts would assist stakeholders to design business strategies accordingly.
? Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
? Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.
KEY MARKET SEGMENTS
• By Type
o Arthrospira Platensis
o Arthrospira Maxima
• By Application
o Nutraceuticals
o Food and Beverages
o Cosmetics
o Agriculture
o Feed
o Others
• By Drug Formulation
o Powder
o Tablet & Capsule
o Liquid
o Granule & Gelling Agent
• By Region
o North America
• U.S.
• Canada
• Mexico
o Europe
• Germany
• France
• Spain
• Italy
• UK
• Rest of Europe
o Asia-Pacific
• Australia
• Japan
• India
• China
• Rest of Asia-Pacific
o LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA
KEY MARKET PLAYERS
• Ligand Pharmaceuticals
• Addrenex Pharmaceuticals
• Shire Plc
• Teva Pharmaceutical Industries Ltd.
• Arena Pharmaceuticals
• Jazz Pharmaceuticals Plc
• Bioprojet
• Graymark Healthcare, Inc.
|
The global elderly & disabled assistive devices market size was $23,009 million in 2018 and is anticipated to reach $35,599 million by 2026, registering a CAGR of 5.5% from 2019 to 2026. Assistive devices, as the term signifies are the medical devices that assist elderly as well as disabled people to form their various basic tasks such as walking, hearing problems, vision problems, and others. The mobility aids devices include wheelchairs, scooters, and others that alleviate disabled individuals with their mobility. Moreover, there are various kinds of hearing aids that help individuals with hearing difficulties such as Behind-the-ear Aids (BTE), Receiver-in-the-Ear Aids (RITE), In-the-Ear Aids (ITE), Bone Anchored Hearing Aids (BAHA), canal hearing aids and cochlear implants.
The global elderly and disabled assistive devices market is primarily driven by significant rise in mobility impairment disorders, lifestyle changes, and availability of a variety of disabled & elderly assistive products. In addition, considerable increase in demand for assistive devices due to rise in trend of an independent lifestyle further fuels the market growth. Furthermore, growth in the number of assistive devices manufacturers investing in the R&D activities of these technologies is estimated to boost the market growth. However, high cost of few sophisticated products, low level of acceptance for few products, and low reimbursement from medical insurers restrain the growth of the market. On the contrary, an increase in proactiveness of people and rise in health consciousness among people are anticipated to provide lucrative growth opportunities for the market growth.
The global elderly & disabled assistive devices market is segmented based on type and region. Based on type, it is divided into living aids, mobility aids devices, medical furniture, and bathroom safety equipment. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
• This report provides an extensive analysis of the emerging trends and dynamics in the global elderly & disabled assistive devices market.
• This study provides the landscape of the global market to predict the competitive environment across geographies.
• This report entails the detailed quantitative analyses of the current trends and future estimations to identify the prevailing opportunities.
• Comprehensive analyses of factors that drive and restrict the market growth is provided in the report.
• Region- and country-wise analysis is conducted to understand the market trends and dynamics.
KEY MARKET SEGMENTS
By Type
• Living Aids Devices
o Hearing Aids
? Behind-the-ear Aids (BTE)
? Receiver-in-the-Ear Aids (RITE)
? In-the-Ear Aids (ITE)
? Bone Anchored Hearing Aids (BAHA)
? Canal Hearing Aids
? Cochlear Implants
o Reading and Vision Aids
? Braille Translators
? Video Magnifiers
? Reading Machines
? Others
• Mobility Aids Devices
o Wheelchairs
? Manual Wheelchairs
? Powered Wheelchairs
o Mobility Scooters
? Walkers & Rollators
? Canes & Walking Sticks
? Crutches
? Transfer Lifts or Patient Mechanical Lift Handling
? Door Openers
? Others
• Medical Furniture
o Medical Beds
o Door Openers
o Medical Furniture Accessories
o Riser Reclining Chairs
o Others
• Bathroom Safety Equipment
o Shower Chairs
o Commodes
o Ostomy Products
o Bars, Grips, & Rails
• By Region
o North America
? U.S.
? Canada
? Mexico
o Europe
? Germany
? France
? UK
? Italy
? Spain
? Rest of Europe
o Asia-Pacific
? Japan
? China
? India
? Australia
? Rest of Asia-Pacific
o LAMEA
? Brazil
? Saudi Arabia
? South Africa
? Rest of LAMEA
The key players profiled in this report are as follows:
• AI Squared
• Drive Medical.
• GN Resound Group.
• Invacare
• William Demant Holding A/S
• Nordic Capital (Sunrise Medical LLC)
• Pride Mobility Products Corporation
• Siemens Ltd
• Sonova Holding AG
• Starkey hearing technologies
The other players operating in the elderly & disabled assistive devices market include (not profiled in the report)
• Bausch & Lomb, Inc.,
• Inclusive Technology Ltd.
• Liberator Ltd.
• Tobii Dynavox
• JABBLA B.V.B.A
• Blue Chip Medical Type, Inc.
• Permobil AB
• Medline Industries, Inc.
|
The global companion diagnostics market generated $1,678 million in 2018, and is projected to reach $6,452 million by 2026, growing at a CAGR of 18.3% from 2019 to 2026.
Companion diagnostic is a medical device, often an in-vitro device that provides information essential for the safe and effective use of a corresponding drug or biological product. These tests help a health care professional to determine patients who can benefit from a particular therapeutic product, identify patients at increased risk of severe side effects as a result of the treatment with a particular therapeutic product as well as achieve improved safety or effectiveness.
The companion diagnostics market is expected to experience significant growth during the forecast period owing to growth in demand for advanced therapies, rise in R&D activities to develop low cost & highly efficient drugs, increase in awareness in personalized medicines and surge in demand for cost effective diagnosis are some factors that majorly drive the market growth.
The global companion diagnostics market is segmented based on technology, indication, and region. Based on technology, the market is categorized as immunohistochemistry, polymerase chain reaction (PCR), next Generation Sequencing (NGS), in situ hybridization, and others. On the basis of indication, it is segmented into oncology, neurology, and others. Oncology is further classified into lung cancer, colorectal cancer, breast cancer, blood cancer, and others. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Technology Type
• Immunohistochemistry
• Polymerase chain reaction (PCR)
• Next Generation Sequencing (NGS)
• In situ hybridization
• Others
Indication
• Oncology
o Lung cancer
o Colorectal cancer
o Breast cancer
o Blood cancer
o Others
• Neurology
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o Rest of Asia-Pacific
• LAMEA
o Brazil
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Abbott Laboratories Molecular, Inc.
• Agilent (Dako Denmark A/S)
• ARUP Laboratories, Inc.
• BioMerieux SA
• Danaher Corporation (Leica Microsystems)
• Foundation Medicine, Inc.
• Myriad Genetics, Inc.
• Qiagen N.V.
• Roche (Ventana Medical Systems, Inc.)
• Thermo Fisher Scientific (Life Technologies Corporation)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• Resonance Health Ltd
|
The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026.
Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.
However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.
The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market.
• Cancer therapeutics market size and market estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry.
• An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
• By Application
o Blood Cancer
o Lung Cancer
o Colorectal Cancer
o Prostate Cancer
o Breast Cancer
o Cervical Cancer
o Head and Neck Cancer
o Glioblastoma
o Malignant Meningioma
o Mesothelioma
o Melanoma
o Others
• By Top Selling Drugs
o Revlimid
o Avastin
o Herceptin
o Rituxan
o Opdivo
o Gleevec
o Velcade
o Imbruvica
o Ibrance
o Zytiga
o Alimta
o Xtandi
o Tarceva
o Perjeta
o Temodar
o Others
• By Region
o North America
? U.S.
? Canada
o Europe
? Germany
? France
? UK
? Italy
? Spain
? Rest of Europe
o Asia-Pacific
? Japan
? China
? India
? Australia
? South Korea
? Taiwan
? Rest of Asia-Pacific
o LAMEA
? Latin America
? Middle-East
? Africa
The list of key players operating in this market include:
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• AbbVie, Inc.
• Johnson & Johnson
• Celgene Corporation
• Astellas Pharma, Inc.
• Pfizer, Inc.
• Novartis AG
• Merck KGaA
• Eli Lilly and Company
The other players included in the value chain analysis (and not included in the report) include:
• AstraZeneca plc
• Bayer AG
• Takeda Pharmaceutical Company Limited
|
Narcolepsy is characterized by several symptoms that include cataplexy, excessive daytime sleepiness, hallucinations, and sleep paralysis. In addition, patients suffering from narcolepsy experience automatic behaviors such as eating, walking, or driving, in a dazed manner. Symptoms differ from patient to patient, and are diagnosed between the ages of 7 and 25. The global narcolepsy drugs market accounted for around $2,429 million in 2018, and is expected to reach $5,360 million by 2026, registering a CAGR of 10.3% from 2019 to 2026.
Although narcolepsy is a rare and underdiagnosed chronic condition, many cases have been reported of the people affected by this disease. It was estimated that more than 1 in 2,000 people in the U.S. were affected by narcolepsy in 2012. Increase in severity of the disease and rise in the number of people being affected by narcolepsy are some of the key driving factors of the market. Furthermore, the availability of reimbursement for FDA-approved prescription medicines is expected to fuel the demand for these drugs. However, lack of awareness regarding the diagnosis and treatment availability hinders the market growth. Conversely, increase in the number of programs by various organizations to spread awareness regarding the importance of early narcolepsy diagnosis is anticipated to offer lucrative opportunities for market expansion.
The global narcolepsy drugs market is segmented based on disease type, therapeutics type, and geography. Depending on disease type, the market is categorized into daytime extreme sleepiness, cataplexia, and others. By therapeutics type, it is segregated into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and others. Region wise, the market is examined across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc., Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc., Bioprojet, and Graymark Healthcare, Inc. have been provided in this report. Product launch and technological advancements are the few strategies adopted by the key players of the global narcolepsy drugs market.
KEY BENEFITS FOR STAKEHOLDERS
? This report highlights the market dynamics to understand the global narcolepsy drugs market and capitalize on the prevailing opportunities.
? Quantitative analysis of the current market and forecasts assists stakeholders to design business strategies accordingly.
? Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
? Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.
KEY MARKET SEGMENTS
• By Disease Type
o Daytime Extreme Sleepiness
o Cataplexia
o Others
• By Therapeutics Type
o Central Nervous System Stimulants
o Tricyclic Antidepressants
o Sodium Oxybate
o Selective Serotonin Reuptake Inhibitor
o Others
• By Region
o North America
• U.S.
• Canada
• Mexico
o Europe
• Germany
• France
• Spain
• Italy
• UK
• Rest of Europe
o Asia-Pacific
• Australia
• Japan
• India
• China
• Rest of Asia-Pacific
o LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA
KEY MARKET PLAYERS
• Ligand Pharmaceuticals
• Addrenex Pharmaceuticals
• Shire Plc.
• Teva Pharmaceutical Industries Ltd.
• Arena Pharmaceuticals
• Jazz Pharmaceuticals Plc.
• Bioprojet
• Graymark Healthcare, Inc.
|
The safety needles market accounted for $1,609 million in 2018, and is expected to reach $3,009 million by 2026, registering a CAGR of 8.1% from 2019 to 2026.
Safety needle is a hollow, cylindrical needle bearing a puncturing point at the tip, which is attached to a syringe. It is used across medical settings in different applications such as drug delivery, vaccination, and blood specimen collection for examination and research purposes. These needles are referred to as safety needles due to the extra function they perform. For instance, these safety devices are equipped with sheaths used to cover the needle to prevent needlestick injuries, which can cause lethal infections. Moreover, these needles use different systems to provide safety against needlestick injuries such as active safety needles require manual activation, whereas passive safety needles do not require any activation and are automatic.
The factors that boost the growth of safety needles market include surge in prevalence of needlestick injuries and increase in cases of chronic diseases & infections. Moreover, other factors that contribute toward the growth of the market include favorable government initiatives related to the use of safety needles. However, factors such as high price of these needles and availability of alternative modes of drug delivery restrain the growth of the market. On the contrary, high growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.
The global safety needle market is segmented based on product, end user, and region. On the basis of product, the market is bifurcated into active safety needles and passive safety needles. By end user, it is categorized into hospitals & ambulatory surgery centers, diabetic patients, family practice, psychiatry, and others. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, Italy, Spain, France, Czech Republic, Republic of Moldova, Poland, Hungary, Romania, Russia, Slovakia, Ukraine, Greece, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan, and, rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, UAE, Qatar, Lebanon, Jordan, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global safety needles market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
• By Product
o Active Safety Needles
o Passive Safety Needles
• By End User
o Hospitals & Ambulatory Surgery Centers
o Diabetic Patients
o Family Practice
o Psychiatry
o Others
o Others
• By Region
o North America
? U.S.
? Canada
? Mexico
o Europe
? Germany
? France
? UK
? Italy
? Spain
? Czech Republic
? Republic of Moldova
? Poland
? Hungary
? Romania
? Russia
? Slovakia
? Ukraine
? Greece
? Rest of Europe
o Asia-Pacific
? Japan
? China
? India
? Australia
? South Korea
? Taiwan
? Rest of Asia-Pacific
o LAMEA
? Brazil
? Saudi Arabia
? South Africa
? UAE
? Qatar
? Lebanon
? Jordan
? Rest of LAMEA
List of key players profiled in the report:
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• Cardinal Health
• Johnson & Johnson (Ethicon Inc.)
• Nipro Corporation
• Novo Nordisk A/S
• Retractable Technologies, Inc.
• Smiths Group Plc.
• Terumo Corporatio
• Vygon SA
LIST of OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• DeRoyal Industries
• Hindustan Syringes & Medical Devices Limited
• Hi-Tech Syringes
|
The global health insurance market was valued at $1,682 million in 2018, and is estimated to reach $2,388 million by 2026, registering a CAGR of 4.4% from 2019 to 2026.
health insurance covers various Health expenses, including the routine of health examinations, unforeseen illnesses or injuries, inpatient & outpatient surgery, specialist referral visits, and prescription medications of insured people. health insurance provides compensation for such medical expenses that may incur, owing to sickness or injury to the insured people in exchange for a monthly premium or a payroll tax to provide the Health benefits.
Health insurance provides coverage to quick suffering diseases with a minimum premium amount. Various governments across the globe provide subsidies for people who cannot afford to pay the premium for health insurance. However, some public health insurance providers do not cover expensive diseases such as cancer and dental recovery.
Increase in the prevalence of chronic diseases such as cardiovascular disease, cancer and diabetes boost the growth of the global health insurance market. In addition, the major factor that drives the growth of the market includes rise in Health expenses. Furthermore, the mandatory provision of health insurance for private and public sector employees propel the market growth. However, term and condition mentioned in health insurance policies, such as limitation of reimbursement in certain hospitals & clinics and elimination of insurance coverage for expensive treatments are expected to hamper the market growth. On the contrary, introduction of advanced health system is expected to serve as a remunerative opportunity for market expansion.
The global health insurance is studied on the basis of provider, insurance type, coverage type demographics, network, and region. By provider, the market is divided into private providers and public providers. Depending on insurance, it is categorized into disease insurance, medical insurance, and income protection insurance. As per coverage type, it is divided into lifetime coverage and term coverage. According to demographics, it is fragmented into minors, adults, and senior citizen. On the basis of network, it is segregated into preferred provider organizations (PPOs), point of services (POS), health maintenance organizations (HMOs), and exclusive provider organizations (EPOs). In-depth analysis of the health insurance market is provided for North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis of the current market trends from 2019 to 2026 to identify the prevailing opportunities.
• Market estimations are based on a comprehensive analysis of the key developments in the industry.
• In-depth analysis based on region assists to understand the regional market to assist in strategic business planning.
• The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Provider
• Private Providers
• Public Providers
By Insurance Type
• Disease Insurance
• Medical Insurance
• Income Protection Insurance
By Coverage Type
• Lifetime Coverage
• Term Coverage
By Demographics
• Minors
• Adults
• Senior Citizen
By Network
• Preferred Provider Organizations (PPOs)
• Point of Services (POS)
• Health Maintenance Organizations (HMOs)
• Exclusive Provider Organizations (EPOs)
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Others
• Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Others
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Others
KEY PLAYERS PRofILED
• Allianz Group
• Assicurazioni Generali S.p.A
• AIA Group Limited
• Anthem, Inc.
• AXA Equitable Life Insurance Company
• China Life Insurance Company Limited
• Munich Re
• Ping An Insurance (Group) Company of China, Ltd.
• State Farm Group
• Zurich Insurance Group.
The other players of the health insurance market in value chain analysis (not included in this report) are
• Berkshire Hathaway Inc.
• Prudential Plc.
• Nippon Life Insurance Company
• Dai-ichi Life Holdings, Inc.
• Kaiser Foundation Group of Health Plans
• Berkshire Hathaway Inc.
• New York Life Insurance Company
• Life Insurance Corporation of India
|
The China oncology drugs market was valued at $6,498.2 million in 2018 and is projected to reach $12,688.7 million by 2026, registering a CAGR of 8.7% from 2019 to 2026. Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer according to the data published by WHO. Being the most populous country in the world, cancer rates are significantly rising in China. As per Global Cancer Observatory in 2018, the number of new cancer cases registered each year in China are 4,285,033. Amongst which, lung cancer constitutes 18.1%; colorectum cancer is about 12.2%; stomach cancer is approximately 10.6%; liver cancer constitutes 9.2%; breast cancer comprises of 8.6% and 41.1% other cancers. The population of China accounts for 19.3% of the global population, and the incidence rate of cancer accounts for 22% of global cancer incidence, ranking first in the world. Cancer deaths in China account for about 27% of global cancer deaths. Cancer mortality in China is also higher than the global average of 17%.
Rise in incidence of various cancer conditions, aging population, westernized diet, shift to sedentary lifestyle, and surge in tobacco smoke exposure due to urbanization in China are the key factors that drive the growth of the cancer. This in turn boosts the growth of the China oncology drugs market. Furthermore, rise in cancer awareness and increase in availability of cancer drugs are expected to boost the market growth. However, the use of traditional Chinese medicine (TCM) to cure cancer and high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies are expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.
The China oncology drugs market is segmented based on drug class type and indication. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer, and other cancers.
KEY MARKET BENEFITS
• This report entails a detailed quantitative analysis along with the current China oncology drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market forecast is studied from 2019 to 2026.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
Key market segments
By Drug Class Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy Therapy
• Hormonal Therapy
By Indication
• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Lung Cancer
• Skin Cancer
• Ovarian Cancer
• Cervical Cancer
• Kidney Cancer
• Other Cancers
LIST of KEY PLAYERS PRofILED IN THE REPORT
• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Shanghai Junshi Biosciences Co., Ltd.
• Beigene
• Jiangsu Hengrui Medicine Co., Ltd
|
The Japan oncology drugs market accounted for $9,405 million in 2018, and is expected to reach $14,109 million by 2026, registering a CAGR of 5.2% from 2019 to 2026.
Cancer is a serious medical condition marked by the presence of tumor cells present in the body. The formation of tumor cells take place when the normal cells grow at an abnormal rate. Moreover, these tumor cells also have the ability to spread to other parts of the body through blood and lymphatic system. In addition, cancer has different stages which are based on the growth pattern of tumor. Therefore, the treatment of cancer differs depending on the stage of cancer. Chemotherapy drugs are mostly employed in the treatment of early stage cancers and similarly targeted therapy and immunotherapy drugs are generally preferred in the treatment of late stage cancers.
Surge in research related to new drug discovery for cancer treatment, rise in incidence of cancer in Japan, and increase in healthcare expenditure boost the growth of Japan oncology drugs market. Moreover, rise in awareness related to early diagnosis of cancer leading to rise in demand of oncology drugs for treatment is another factor that fuels the growth of the market in Japan. Furthermore, surge in geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancer such as prostate cancer. In addition, rise in number of pipeline products is expected to provide lucrative opportunities during the forecast period. Conversely, stringent approval process of oncology drugs in Japan hinders the growth of market.
The Japan oncology drugs market size is studied based on segments, drug class type and indication. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer and others.
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the Japan market
• A qualitative analysis based on innovative products facilitates strategic business planning.
Key Market Segments
By Drug Class Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy (Biologic Therapy)
• Hormonal Therapy
By Indication
• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Lung Cancer
• Skin Cancer
• Ovarian Cancer
• Cervical Cancer
• Other Cancers
List of key players profiled in the report:
• Otsuka Holdings Co Ltd
• Johnson and Johnson
• Daiichi Sankyo Co Ltd
• AstraZeneca plc
• AbbVie Inc.
• Celgene Corporation
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Ltd
LIST of OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Sanofi
• Amgen Inc.
• Bayer AG
|
The global mobile gamma cameras market size was $XX million in 2018 and is projected to reach $XX million by 2026, growing at a CAGR of XX% from 2019 to 2026.
Mobile gamma camera system is an imaging technique to generate functional scans of small and large organs including brain, cardiac, neurological, breast, thyroid, pancreas and kidney applications. The mobile gamma camera scans the body by using a procedure that follows injecting a radionucleotide in the body or organ and then recording the resulting radioactivity by image scanning. In mobile gamma camera the total examination time is ten minutes till final images. Further, mobile gamma camera system can be used at bedside and is greater in clinical practices. Nuclear imaging is performed due to its better selectivity and resolution. Thus, it is vastly used at the time of surgery in the healthcare sector. In addition, a rise in number of applications of mobile gamma camera devices is expected to reduce the costs of hospitalization without threatening the safety of patients.
The global mobile gamma cameras market is experiencing growth owing to factors such as advantages of mobile gamma cameras over traditional gamma cameras, and technological advancements in expanding the imaging options. Further, factors such as rise in prevalence of chronic diseases in near future, fuel the growth of the global mobile gamma cameras market. However, side effects such as decrease in organ function, hair loss and skin burn of mobile gamma cameras and exposure to a lethal dose of gamma radiation are certain factors which hamper the growth of the global mobile gamma cameras market. On the contrary, development of mobile gamma camera is slowly replacing the conventional cameras, and this represents the biggest technological development in the market followed by miniaturization and numerous developments in the radionucleotide, which are anticipated to create newer opportunities in the emerging as well as the developed markets.
The global mobile gamma cameras market is segmented based on product type, application, end user, and region to provide a detailed assessment of the market. Based on product type, the market is classified into single-head mobile gamma cameras, dual-head mobile gamma cameras, triple-head mobile gamma cameras, and handheld mobile gamma camera. Based on application, the market is segmented into cardiac imaging, breast imaging, thyroid scanning, kidney scanning, intraoperative imaging, and others. Based on end user, it is classified into hospital, imaging centers & clinics, and research centers. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
? This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2028, which assists to identify the prevailing market opportunities.
? An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
? A comprehensive analysis of the factors that drive and restrain the growth of the global mobile gamma cameras market is provided.
? An extensive analysis of various regions provides insights that allows companies to strategically plan their business moves.
KEY MARKET SEGMENTS
• By Product type
o Single-head Mobile Gamma Cameras
o Dual-head Mobile Gamma Cameras
o Triple-head Mobile Gamma Cameras
o Handheld Mobile Gamma Camera
• By Application
o Cardiac Imaging
o Breast Imaging
o Thyroid Scanning
o Kidney Scanning
o Intraoperative Imaging
o Other
• By End User
o Hospital
o Imaging Centers & Clinics
o Research Centers
• By Region
o North America
? U.S.
? Canada
? Mexico
o Europe
? Germany
? France
? Spain
? Italy
? UK
? Rest of Europe
o Asia-Pacific
? Japan
? India
? China
? South Korea
? Rest of Asia-Pacific
o LAMEA
? Brazil
? Saudi Arabia
? South Africa
? Rest of LAMEA
KEY MARKET PLAYERS
• Dilon Technologies, Inc
• General Electric Company (GE Healthcare)
• Digirad Corporation
• DDD-Diagnostic A/S
• GAEDE Medizinsysteme GmbH,
• Adolesco AB, MiE GmbH
• Gamma Medica, Inc.
• Crystal Photonics GmbH
• Oncovision.
|
The Australia & New Zealand fertility services market generated $709 million in 2018, and is projected to reach $1,020 million by 2026, growing at a CAGR of 4.6% from 2019 to 2026.
Fertility services are treatments that assist in treating infertility in patients. In vitro fertilization (IVF), surrogacy, intrauterine insemination, and others are different forms of infertility services that help single mothers, couples with infertility problems, and people from the LGBT community to procreate.
The Australia & New Zealand fertility services market is expected to witness a substantial growth in the future, owing to higher number of infertility cases, emerging trend of delayed pregnancies among women, rise in technological advancements in fertility procedures, and large presence of fertility clinics with trained medical professionals. In addition, availability of advanced fertility treatments, increase in disposable income, and favorable reimbursement policies further augment the market growth in Australia & New Zealand. In addition, recent innovations in IVF technology with surge in assisted reproductive technology (ART) success rate are projected to boost the demand for fertility services in the future. However, higher cost, complications associated with ART treatment, and multiple pregnancies associated with fertility treatments are projected to hinder the market growth. Rise in new fertility clinics and increase in same-sex marriages are projected to offer lucrative growth opportunities in future.
The Australia & New Zealand fertility services market is segmented based on procedure, service, and end user. Based on procedure, the market is divided into IVF with intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), IVF without ICSI, surrogacy, and others. Based on service, it is categorized into fresh non-donor, frozen non-donor, egg and embryo banking, fresh donor, and frozen donor. Based on end user, the market is segmented into fertility clinics, hospitals, surgical centers, and clinical research institutes.
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Procedure
o IVF with ICSI
o IUI
o IVF without ICSI
o Surrogacy
o Others
Service
o Fresh Non-donor
o Frozen Non-donor
o Egg and Embryo Banking
o Fresh Donor
o Frozen Donor
End User
o Fertility Clinics
o Hospitals
o Surgical Centers
o Clinical Research Institutes
LIST of KEY PLAYERS PRofILED IN THE REPORT
• Adora Fertility
• Care Fertility
• City Fertility
• Fertility Associates Limited
• Fertility First
• Fertility SA
• GENEA LIMITED
• Monash IVF Group Limited
• National Women’s Health
• Virtus Health
LIST of OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• Demeter Fertility
• Coastal IVF
• Melbourne IVF
|
The Germany IVF market was valued at $398 million in 2018 and is estimated to reach $541 million by 2026, registering a CAGR of 3.9% during the analysis period.
In vitro fertilization (IVF) is a process that includes fertilization of egg cells outside the body. It is one of the widely known infertility treatment across the clinical industry. The technique is based on assisted reproductive technology and is employed in the treatment of infertility. The process involves removing an ovum (egg or eggs) the ovaries and facilitating its fertilization with the help of a sperm in a laboratory dish. After the fertilized egg (zygote) undergoes embryo culture for up to 6 days, it is implanted in another or same woman's uterus, depending on the conditions. IVF helps achieve pregnancy when other treatments fail. It is generally not used until less expensive or invasive options have failed or been determined unlikely to work.
Subsidizing IVF treatments, delayed marriages and parenthood decisions, and increase in prevalence of infertility issues are the factors that majorly drive the growth of the IVF market in Germany. In addition, as per National Health Plan (NHP), about 50% of the treatment cost by IVF paid for three cycles is projected to boost growth of the IVF market in Germany. However, stringent government regulations and lack of availability in treatment cycles for IVF are the major restraints that hamper the growth of the market in Germany.
The Germany in vitro fertilization market (IVF) is segmented based on cycle type and end user. Based on cycle type, the market is divided into fresh IVF cycles (non-donor), and thawed IVF cycles (non-donor). Based on end user, the market is classified into fertility clinics, hospitals, surgical centers, and clinical research institutes.
KEY MARKET BENEFITS
• The study provides an in-depth analysis of the Germany in vitro fertilization (IVF) market along with the current trends and future estimations to elucidate the imminent investment pockets.
• The report presents a quantitative analysis of the market from 2018 to 2026 to enable stakeholders to capitalize on the prevailing market opportunities.
• An extensive analysis of the market based on application assists in understanding the trends in the industry.
• The key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.
KEY MARKET SEGMENTS
Germany In Vitro Fertilization Market
By Cycle Type
o Fresh IVF Cycles (Non-donor)
o Thawed IVF Cycles (Non-donor)
By End User
o Fertility Clinics
o Hospitals
o Surgical Centers
o Clinical Research Institutes
LIST of KEY PLAYERS PRofILED IN THE REPORT
• Heidelberg University Hospital
• Klinikum Stuttgart
• DRK Kliniken Berlin
• University Medical Center Freiburg
|
The UK IVF market was valued at $514 million in 2018 and is estimated to reach $928 million by 2026, registering a CAGR of 7.6% during the analysis period.
In-vitro-Fertilization (IVF) is a common artificial infertility treatment performed in the laboratory. The treatment involves removing an ova (egg or eggs) or ovum from the ovaries and allowing sperm to fertilize them in a laboratory dish. It is a form of assisted reproductive technology based fertility treatment across the clinical industry. The process involves five major steps such as stimulation, egg retrieval, insemination & fertilization, embryo culture, and embryo transfer, which is completed over a course of several months. After the fertilized egg (zygote) undergoes embryo culture for up to 6 days, it is implanted in another or same woman's uterus. In vitro fertilization can help conceive when other natural treatments have failed.
The UK invitro fertilization market is on the rise owing to increase in awareness about assisted reproductive technology, favorable regulations for IVF, and commercialization of three-parent IVF procedures. In addition, rise in awareness about assisted reproductive technology is expected to boost the UK IVF market. However, ethical considerations by social and religious organizations, and cost of the treatment are expected to hinder the growth of the IVF market in the UK. However, involvement of social and religious organizations for revaluation of the IVF legislation in the UK hinders the growth of the market. Furthermore, surge in technical advancements related IVF technique is projected to provide lucrative opportunities during the forecast period.
The UK in vitro fertilization market (IVF) is segmented based on cycle type, and end user. Based on cycle type, the market is divided into fresh IVF cycles (non-donor), thawed IVF cycles (non-donor), and donor egg IVF cycles. Based on end user, the market is classified into fertility clinics, hospitals, surgical centers, and clinical research institutes.
KEY MARKET BENEFITS
• The study provides an in-depth analysis of the UK in vitro fertilization (IVF) market along with the current trends and future estimations to elucidate the imminent investment pockets.
• The report presents a quantitative analysis of the market from 2018 to 2026 to enable stakeholders to capitalize on the prevailing market opportunities.
• An extensive analysis of the market based on application assists in understanding the trends in the industry.
• The key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.
KEY MARKET SEGMENTS
UK In Vitro Fertilization Market
By Cycle Type
o Fresh IVF Cycles (non-donor)
o Thawed IVF Cycles (non-donor)
o Donor Egg IVF Cycles
By End User
o Fertility Clinics
o Hospitals
o Surgical Centers
o Clinical Research Institutes
LIST of KEY PLAYERS PRofILED IN THE REPORT
• The Lister Fertility Clinic
• The Bridge Centre
• Chelsea and Westminster Hospital (Assisted Conception Unit)
|
The near infrared imaging market accounted for $271 million in 2018, and is expected to reach $375 million by 2026, registering a CAGR of 4.1% from 2019 to 2026.
Near infrared (NIR) is a sub-division of the infrared band of the electromagnetic spectrum having wavelength ranging from 0.7 to 1.4 microns, which is very close to human vision. NIR imaging technique involves the use of near infrared light to obtain images of tissues. These systems rely on fluorescent dye, which is administered to obtain fluorophore emission. These emissions are captured by an imaging system and camera. This further produces real time images of the tissues. It is advantageous over other techniques since it provides better resolution and is less harmless to patients. NIR Imaging can be helpful in diagnosing breast cancer, depression, Alzheimer’s disease, and schizophrenia. Near infrared imaging is used as a replacement for far infrared and thermal vision. It is advantageous over thermal vision since thermal vision can only absorb heat and does not product clear images.
Rise in number of surgical procedures worldwide for cancer surgery, gastrointestinal surgery, and cardiovascular surgery, plastic/reconstructive surgeries coupled with surge in prevalence of target diseases such as lung cancer, breast cancer, colon cancer, and prostate cancer; increasing prevalence of chronic diseases and neurological disorders, are responsible for driving the growth of near infrared imaging market. In addition, surge in adoption of NIR imaging across the globe, rise in geriatric population and health awareness in the emerging economies are the prime growth factor for the growth of global near infrared imaging market. However, high availability of other alternative imaging techniques and high price of infrared detectors may restrict the global near infrared imaging market.
The near infrared imaging market is segmented based on product, application, indication, end user, and region to provide a detailed assessment of the market. Based on product, the market is divided into near infrared fluorescence imaging systems and near infrared fluorescence & bioluminescence imaging systems. Based on application, the near infrared imaging market is classified into pre-clinical imaging, medical imaging and clinical imaging. Based on indication, the near infrared imaging market is segmented into cancer surgeries, cardiovascular surgeries, gastrointestinal surgeries, plastic/reconstructive surgeries, and others. Based on end user, the market is divided into hospitals and clinics, research laboratories and others. Based on region, the near infrared imaging market size is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global near infrared imaging market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
• By Product
o Near Infrared Fluorescence Imaging Systems
o Near Infrared Fluorescence & Bioluminescence Imaging Systems
• By Application
o Pre-clinical Imaging
o Medical Imaging (Diagnostic and Surgeries)
o Clinical Imaging
• By Indication
o Cancer Surgeries
o Cardiovascular Surgeries
o Gastrointestinal Surgeries
o Plastic/Reconstructive Surgeries
o Others
• By End User
o Hospitals & Clinics
o Research Laboratories
o Others
• By Region
o North America
? U.S.
? Canada
? Mexico
o Europe
? Germany
? France
? UK
? Italy
? Spain
? Rest of Europe
o Asia-Pacific
? Japan
? China
? India
? Australia
? South Korea
? Rest of Asia-Pacific
o LAMEA
? Brazil
? Saudi Arabia
? South Africa
? Rest of LAMEA
List of key players profiled in the report:
• Carl Zeiss AG
• Danaher Corporation (Leica Microsystems)
• Hamamatsu Photonics K.K.
• Karl Storz SE & Co. KG
• Li-Cor, Inc.
• Medtronic plc.
• PerkinElmer Inc.
• Quest Innovations B.V. (Quest Medical Imaging B.V.)
• Shimadzu Corporation
• Stryker Corporation
LIST of OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Fluoptics
• Mizuho
• Olympus
• Hitachi, Ltd.
|
The global beta-lactam and beta-lactamase inhibitors market size was $27,126 million in 2018, and is projected to reach $34,170 million by 2028, growing at a CAGR of 2.3% from 2019 to 2028.
Beta-lactam and beta-lactamase inhibitors is a most important type of antibacterial agent used for fighting bacterial infections. In addition, these are used to kill or prevent the growth of microorganisms. Based on the molecular structure, beta-lactam and beta-lactamase inhibitors are drug classified into penicillin, cephalosporin, carbapenem, monobactam, and combination.
There is an increase in the demand for beta-lactam and beta-lactamase inhibitors, owing to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections and a large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitors and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.
The global beta-lactam and beta-lactamase inhibitors market is segmented based on drug class, disease, route of administration, and region. Based on the drug class, the market is classified into penicillin, cephalosporin, carbapenem, monobactam, and combination. Combination segment is further categorized into penicillin/beta lactamase inhibitors, cephalosporins/beta lactamase inhibitors, and carbapenems/beta lactamase inhibitors. Depending on the disease segment, the market is divided into urinary tract infection (excluding cUTI), respiratory infection, skin infection, complicated urinary tract infection (cUTI), complicated intra-abdominal infections (cIAI), nosocomial pneumonia, blood stream infection, and other diseases. Nosocomial pneumonia segment is further divided into hospital acquired pneumonia, ventilator associated pneumonia, and other nosocomial pneumonia. Based on route of administration, the market is classified into oral, intravenous, and others. Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
? This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2028, which assists to identify the prevailing market opportunities.
? An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
? A comprehensive analysis of the factors that drive and restrain the growth of the global beta-lactam and beta-lactamase inhibitors market is provided.
? An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
• By Drug Class
o Penicillin
o Cephalosporin
o Carbapenem
o Monobactam
o Combination
? Penicillin/Beta Lactamase Inhibitors
? Cephalosporins/Beta Lactamase Inhibitors
? Carbapenems/Beta Lactamase Inhibitors
• By Disease
o Urinary Tract Infection (excluding cUTI)
o Respiratory Infection
o Skin Infection
o Complicated Urinary Tract Infection (cUTI)
o Complicated Intra-Abdominal Infections (cIAI)
o Nosocomial Pneumonia
? Hospital Acquired Pneumonia
? Ventilator Associated Pneumonia
? Other Nosocomial Pneumonia
o Blood Stream Infection
o Other Diseases
• By Route of Administration
o Oral
o Intravenous
o Others
• By Region
o North America
? U.S.
? Canada
? Mexico
o Europe
? Germany
? France
? Spain
? Italy
? UK
? Rest of Europe
o Asia-Pacific
? Japan
? India
? China
? South Korea
? Thailand
? Taiwan
? Vietnam
? Rest of Asia-Pacific
o LAMEA
? Brazil
? Saudi Arabia
? South Africa
? Rest of LAMEA
KEY MARKET PLAYERS
• Abbott Laboratories
• Allergan Plc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Mylan N.V.
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
The other players in the value chain (profiles not included in the report)
• Hikma Pharmaceuticals
• Melinta Therapeutics
• Eli Lilly and Company
• Shionogi, Inc.
• AstraZeneca plc
|